Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    lexatumumab
Show Display Options
Rank Status Study
1 Terminated HGS-ETR2 to Treat Children With Solid Tumors
Conditions: Ewing's Sarcoma;   Osteosarcoma;   Neuroblastoma;   Rhabdomyosarcoma
Interventions: Drug: Lexatumumab alone;   Drug: Lexatumumab in combination;   Drug: Interferon gamma 1b in combination;   Drug: Gamma 1b potential expansion
2 Not yet recruiting Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Metastatic Malignant Neoplasm in the Lymph Nodes;   Recurrent Gastric Carcinoma;   Stage IV Gastric Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Biological: Ramucirumab

Study has passed its completion date and status has not been verified in more than two years.